Dubai – A workshop organized by the World Health Organization (WHO) is currently underway in Dubai, UAE, focusing on the risk-benefit assessment of snake antivenom immunoglobulin products.

The event, which runs from December 3-4, 2024, brings together regulators, procurement agencies, and manufacturers from Africa, the Middle East, and South
Asia.

Razi Vaccine & Serum Research Institute as the first manufacturer of antivenom immunoglobulin products in the Middle East is actively participating in this workshop to understand how the risk-benefit assessment process can help to improve RVSRI’s production of life-saving products and to identify common deficiencies that arise and correct them through better self-inspection practices.
 
The workshop aims to address the critical issue of snakebite envenoming, a significant public health problem in these regions. By improving the assessment process for snake antivenom products, the WHO hopes to enhance their quality, safety, and efficacy.